Acorda: secondary endpoints supportive of primary endpoint in INBRIJA trial

Acorda Therapeutics announced that The Lancet Neurology published results from SPANSM-PD, the Phase 3 pivotal efficacy trial of INBRIJA, also referred to as CVT-301. In the study, INBRIJA 84 mg significantly improved motor function at 30 minutes during OFF periods in people with Parkinson’s taking carbidopa/levodopa, the study’s primary endpoint. Onset of action was seen as early as 10 minutes and the reduction at 30 minutes was maintained at 60 minutes. Multiple secondary endpoints were supportive of the primary endpoint. Data from the study were first presented at the 2017 International Congress of Parkinson’s Disease and Movement Disorders. “A well-tolerated, effective treatment for OFF periods between doses of scheduled medications can help fulfill one of the most important unmet needs for people with Parkinson’s,” said lead author of the publication Peter LeWitt, M.D., Director of the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital and professor of neurology at Wayne State University School of Medicine. “The data published in The Lancet Neurology support INBRIJA as such a treatment option, delivering levodopa, the current ‘gold standard’ of Parkinson’s treatment, in a novel, inhaled form.”

https://thefly.com/landingPageNews.php?id=2850635